Safer drugs for children. by unknown
Forum
IgE bound to its receptor. "It may be more
fruitful for drug development ifwe can get
a picture ofthis 'lock and key' mechanism,"
says Jardetzky. "From that, it may emerge
that it is better to design an inhibitor for
the antibody than for the receptor."
Because allergic responses result only
from IgE binding to the IgE receptor, ther-
apeutic strategies aimed at inhibiting
IgE-receptor interactions could provide a
single treatment to fight multiple condi-
tions such as asthma and sinusitis. The
researchers believe that blocking the IgE
receptor from binding the IgE antibody
will short-circuit the allergy cycle.
Because the IgE-receptor interaction
controls only the allergy branch of the
body's immune response, it could be
inhibited without compromising the entire
immune response, says Kinet. The IgE
receptor is thought to play some as-yet
undefined role in immunity to parasitic
infections. Jardetzky allows that inhibition
of the IgE-receptor interaction may result
in susceptibility to parasitic infections, par-
ticularly in developing nations, where such
diseases are endemic. However, notes
Kinet, IgE is not the only natural defense
the body has against parasites. The advan-
tages offered by such an inhibitor, he says,
would far outweigh the disadvantages.
Safer Drugs for Children
When prescribing drugs for children, pedia-
tricians must often resort to guess-
work in determining the appropriate
dose as well as in assessing the effec-
tiveness of most pharmaceuticals
currently on the market. While
drug testing on humans has been
required by the Food and Drug
Administration (FDA) since the
1960s, an overwhelming majority
ofthe testing has been conducted
on adults. As of 1 April 1999,
however, the FDA is requiring
drug manufacturers to provide
sufficient data and labeling on
the safe use ofdrugs in children.
"Pediatricians and other
health care providers will now
have more specific dosing infor-
mation based on scientific evi-
dence," said First Lady Hillary
Rodham Clinton in an FDA press
release announcing the regulation.
"This will make prescribing medica-
tion for children safer and may also
lessen the number ofside effects."
In 1994, the FDA issued a regula-
tion that simplified the pediatric data
required to obtain pediatric labeling in
order to encourage drug manufacturers to
voluntarily submit such data. The effort was
unsuccessful, and about 75% ofdrugs cur-
rently on the market still lack adequate
pediatric labeling.
In 1997, Congress passed the Food and
Drug Administration Modernization Act
and established an incentive-six months of
protected market exclusivity-for manufac-
turers to conduct tests on the effects of
drugs frequently used in children. The act's
provision for exclusivity is applicable until
2002. "That exclusivity solves some of the
missing information problem," says Diane
Murphy, associate director for pediatrics at
the FDA, "but it doesn't apply to products
that don't have a patent."
The FDA issued a regulation in
November 1998 (which became effective
last April) that requires manufacturers to
assess the safety and effectiveness ofall drugs
that are therapeutically important or com-
monly prescribed for children. The new rule
also requires that some drugs already on the
market be tested ifthey are commonly pre-
scribed for use in children and ifthe absence
of adequate labeling could pose significant
risks to children.
In some cases, pediatric data can be sub-
mitted to the FDA after a new drug has
been approved, especially if the FDA has
safety concerns about testing the drug on
children. "We are not going to hold up a
therapy for adults just because we don't
have all the information for children,"
Murphy says. Deferrals for pediatric testing
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may be granted in such cases.
The pediatric data requirement can be
waived entirely ifthe product does not pro-
vide a meaningful therapeutic benefit over
existing treatments and is not likely to be
used in more than 50,000 pediatric
patients. Waivers may also be granted for
products that are likely to be unsafe or inef-
fective in pediatric patients (the assumption
being that they will not be prescribed for
children), if pediatric studies are impracti-
cal, or if reasonable efforts to develop a
pediatric formulation have failed.
As for concerns about testing drugs on
children, Robert Ward, a professor ofpedi-
atrics at the University ofUtah in Salt Lake
City and chair ofthe American Academy of
Pediatrics Committee on Drugs, says there
is extensive literature on how to study drugs
in children. Ward says there is a general
consensus that the metabolism and safety of
a drug should be demonstrated in adults
before being tested in children. The main
issue to remember about pediatric drug test-
ing, he says, is that it comes down to a
choice of giving a child a drug under care-
fully controlled study conditions, or possi-
bly giving a child a drug that has not been
thoroughly tested in children.
There is more at issue than children's
health. The FDA estimates that pediatric
testing will cost less than 1% of the total
spent to develop a new drug, or less than
$50 million a year for all pediatric testing.
However, health care savings due to better
drug treatments for children are estimated
to be $100 million annually.
The National Pharmaceutical Alliance
and the Generic Drug Industry Association
filed a lawsuit in federal court on 19
February 1999 opposing the FDA's inter-
pretation ofthe exclusivity extensions in the
act and requesting that the FDA be stopped
from enforcing the rules.
The industry is arguing that the FDA
has expanded the exclusivity to all forms of
a particular drug, not just the form or forms
used in children. The provision was intend-
ed as an incentive, says Michael Hinckle, an
attorney representing the generic industry,
but the way that the FDA has interpreted it
has resulted in a windfall for brand name
pharmaceutical companies. "This broad
interpretation will cause considerable hard-
ship to the generic industry," Hinckle says.
The American Academy of Pediatrics
filed to intervene in the lawsuit and argue
on behalf of children, but the motion was
denied. "In 1968, the lack of studies on
children was first pointed out," says Ward;
this lack of data remains today. "There is
finally some movement," he says, "and the
generics are potentially going to stop that
process.
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